Product Information
GABAPENTIN 300 MG CAPSULE is a generic product labeled by ScieGen Pharmaceuticals, Inc., priced at $0.0314 per EA under NDC 50228018010. Its NADAC has been published 282 times since May 12, 2021.
FDA first approved this application on Feb 18, 2016. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the Gabapentin market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
300 mg/1
Manufacturer
ScieGen Pharmaceuticals, Inc.NDC
50228018010
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
GABAPENTINApproval Type
Generic (ANDA)
FDA Application
ANDA204989FDA Approved
2/18/2016
TE Code
AB
On Market Since
2/18/2016
Pharmacological Classes
Price Statistics
The NADAC for GABAPENTIN 300 MG CAPSULE has been published 282 times since May 12, 2021, and over the history we have for it it has declined 34.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0314 per EA |
|---|---|
| All-time high | $0.0537 (Nov 10, 2021) |
| All-time low | $0.0301 (Aug 19, 2026) |
| 52-week high | $0.0351 |
| 52-week low | $0.0301 |
| Median price | $0.0408 |
| Average price | $0.0407 |
| Largest weekly change | -17.0% (Nov 20, 2024) |
| Weeks tracked | 282 |
| Tracking since | May 12, 2021 |
Generic Alternatives
The matcher finds 17 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 4% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
ScieGen Pharmaceuticals, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Gabapentin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of GABAPENTIN 300 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for GABAPENTIN 300 MG CAPSULE, manufactured by ScieGen Pharmaceuticals, Inc., is $0.0314 per EA (NDC 50228018010), effective Sep 30, 2026.
How has the price of GABAPENTIN 300 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for GABAPENTIN 300 MG CAPSULE has declined 34.5%. It has been tracked across 282 weekly CMS publications since May 12, 2021.
What are the highest and lowest recorded NADAC prices for GABAPENTIN 300 MG CAPSULE?
Since May 12, 2021, the NADAC for GABAPENTIN 300 MG CAPSULE has ranged from a low of $0.0301 (Aug 19, 2026) to a high of $0.0537 (Nov 10, 2021), with a median of $0.0408 per EA.
Are there cheaper alternatives to GABAPENTIN 300 MG CAPSULE?
Yes. 17 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, GABAPENTIN 300 MG CAPSULE, is $0.0301 per EA — about 4% below GABAPENTIN 300 MG CAPSULE.
Who manufactures GABAPENTIN 300 MG CAPSULE?
GABAPENTIN 300 MG CAPSULE (NDC 50228018010) is labeled by ScieGen Pharmaceuticals, Inc., and CMS classifies it as a generic product.